Veeral H. Ajmera, Norah A. Terrault, Stephen A. Harrison – 18 January 2017 – Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied.

Càndid Villanueva, Isabel Graupera, Carles Aracil, Edilmar Alvarado, Josep Miñana, Ángela Puente, Virginia Hernandez‐Gea, Alba Ardevol, Oana Pavel, Alan Colomo, Mar Concepción, María Poca, Xavier Torras, Josep M. Reñe, Carlos Guarner – 18 January 2017 – Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB.

Zongwen Shuai, Jinjun Wang, Madhu Badamagunta, Jinjung Choi, Guoxiang Yang, Weici Zhang, Thomas P. Kenny, Kathryn Guggenheim, Mark J. Kurth, Aftab A. Ansari, John Voss, Ross L. Coppel, Pietro Invernizzi, Patrick S.C. Leung, M. Eric Gershwin – 18 January 2017 – The identification of environmental factors that lead to loss of tolerance has been coined the holy grail of autoimmunity.

Thomas R. O'Brien, Shyam Kottilil, Jordan J. Feld, Timothy R. Morgan, Ruth M. Pfeiffer – 18 January 2017

Feng Su, George N. Ioannou – 18 January 2017

Veeral H. Ajmera, Norah A. Terrault, Stephen A. Harrison – 18 January 2017 – Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied.

David S. Goldberg – 17 January 2017

Elizabeth C. Verna – 17 January 2017

Cynthia Levy – 17 January 2017

Payal Arora, Amartya Basu, M. Lee Schmidt, Geoffrey J. Clark, Howard Donninger, Daniel B. Nichols, Diego F. Calvisi, Neerja Kaushik‐Basu – 16 January 2017 – Hepatitis C virus (HCV) infection is a common risk factor for the development of liver cancer. The molecular mechanisms underlying this effect are only partially understood. Here, we show that the HCV protein, nonstructural protein (NS) 5B, directly binds to the tumor suppressor, NORE1A (RASSF5), and promotes its proteosomal degradation.